Cardiovascular Drugs Practice Questions

Q: A 40-year-old male presents to the emergency department with an altered level of consciousness. On examination, his blood pressure is 210/152 mmHg and he has severe papilledema. Which of the following drugs, administered via intravenous infusion, acts on GPCRs and has a very short duration of action?

Fenoldopam. ### Explanation **Correct Answer: A. Fenoldopam** The patient is presenting with a **Hypertensive Emergency** (BP >180/120 mmHg with target organ damage, evidenced by altered consciousness and papilledema) [1]. **Why Fenoldopam is correct:** * **Mechanism of Action:** Fenoldopam is a selective **Dopamine D1 receptor agonist**. Since D1 receptors are **G-Protein Coupled Receptors (GPCRs)**, it fits the question's criteria. * **Pharmacokinetics:** It is administered via IV infusion and has a **very short half-life** (approx. 5–10 minutes), allowing for precise titration. * **Clinical Benefit:** It causes systemic vasodilation and, uniquely, increases renal blood flow and promotes natriuresis, making it highly beneficial in patients with renal impairment. **Why the other options are incorrect:** * **B. Hydralazine:** It is a direct vasodilator [2]. While used in pregnancy-induced hypertension, its duration of action is longer and less predictable, and its primary mechanism is not via GPCRs. * **C. Metoprolol:** While it acts on GPCRs ($\beta_1$ receptors), it is a $\beta$-blocker. In hypertensive emergencies, pure $\beta$-blockers are rarely first-line unless there is aortic dissection, as they can cause "unopposed alpha activity." * **D. Nitroprusside:** Although it is short-acting and used in emergencies, it acts by releasing **Nitric Oxide (NO)**, which directly activates **soluble Guanylyl Cyclase** [2]. It does not act via a GPCR. **High-Yield Clinical Pearls for NEET-PG:** * **Fenoldopam side effect:** It can increase intraocular pressure; use with caution in **Glaucoma**. * **Nitroprusside toxicity:** Prolonged infusion can lead to **Cyanide/Thiocyanate toxicity** (treated with Sodium Thiosulfate). * **Drug of Choice (DOC):** For most hypertensive emergencies, **Labetalol** or **Nicardipine** are commonly used, but Fenoldopam is the specific answer when "D1 agonist" or "renal preservation" is hinted.

Q: All are true about Carvedilol except?

It is a cardioselective beta-blocker. **Explanation:** **Why Option C is the correct answer (The "Except" statement):** Carvedilol is a **non-selective beta-blocker** (blocks both $\beta_1$ and $\beta_2$ receptors) that also possesses **$\alpha_1$-blocking** activity. [1] It does not exhibit cardioselectivity. Cardioselective beta-blockers (like Metoprolol, Bisoprolol, and Atenolol) primarily target $\beta_1$ receptors. Carvedilol’s additional $\alpha_1$ blockade leads to peripheral vasodilation, which reduces afterload—a distinct advantage in managing heart failure. **Analysis of other options:** * **Option A:** Carvedilol is a first-line agent in **Chronic Congestive Heart Failure (CHF)**. It reduces remodeling, decreases mortality, and improves ejection fraction. [3] * **Option B:** Beyond receptor blockade, Carvedilol has unique **antioxidant** (scavenges free radicals) and **anti-inflammatory** properties, which protect the myocardium from oxidative stress. [1] * **Option D:** In CHF, beta-blockers must be started at **"low dose and titrated slowly"** (Start low, go slow). This prevents acute decompensation due to the initial negative inotropic effect, allowing the heart to adapt to the long-term benefits of sympathetic blockade. **High-Yield Clinical Pearls for NEET-PG:** * **Generation:** Carvedilol is a **3rd generation** (vasodilatory) beta-blocker. [2] * **Lipophilicity:** It is highly lipid-soluble and undergoes extensive first-pass metabolism. * **Metabolic Profile:** Unlike older beta-blockers, Carvedilol is metabolically neutral or may improve insulin sensitivity. * **FDA Approved for CHF:** Only three beta-blockers are proven to reduce mortality in CHF: **Carvedilol, Bisoprolol, and Metoprolol Succinate** (long-acting). [2], [3]

Q: The toxic effect of beta receptor antagonists includes all of the following EXCEPT?

Precipitate migrainic effect. **Explanation:** Beta-receptor antagonists (Beta-blockers) are widely used in cardiovascular medicine, but their side-effect profile is a high-yield topic for NEET-PG. **Why Option D is the correct answer:** Beta-blockers (specifically Propropanol) are actually a **first-line treatment for the prophylaxis of migraine**. They work by preventing vasodilation and modulating central neurotransmission. Therefore, they do not "precipitate" migraine; rather, they prevent it. **Analysis of Incorrect Options:** * **A. Hypoglycemic episodes:** Beta-blockers mask the sympathetic warning signs of hypoglycemia (tachycardia, tremors) and inhibit glycogenolysis/gluconeogenesis. This can lead to severe, "silent" hypoglycemia in diabetic patients. * **B. Worsening of asthma:** Non-selective beta-blockers (like Propranolol) block $\beta_2$ receptors in the bronchi, leading to bronchoconstriction. This can trigger life-threatening bronchospasm in patients with asthma or COPD. * **C. Ischemic cardiac episodes:** Chronic use of beta-blockers leads to **up-regulation** of beta receptors. Abrupt discontinuation causes a "rebound" effect where endogenous catecholamines overstimulate these receptors, leading to severe hypertension, angina, or myocardial infarction. **Clinical Pearls for NEET-PG:** 1. **Cardioselective Beta-blockers ($\beta_1$):** Remember the mnemonic **"MANBABE"** (Metoprolol, Atenolol, Nebivolol, Bisoprolol, Acebutolol, Betaxolol, Esmolol). These are safer (but not absolute) in asthma and diabetes. 2. **Lipid Profile:** Beta-blockers can increase triglycerides and decrease HDL levels. 3. **Peripheral Vascular Disease:** They can worsen Raynaud's phenomenon due to unopposed $\alpha$-mediated vasoconstriction. 4. **Esmolol:** Shortest acting beta-blocker (half-life ~9 mins), administered IV for hypertensive emergencies or supraventricular tachycardia.

Q: All of the following statements about Digoxin-induced arrhythmias are true, EXCEPT?

Biventricular Tachycardia. **Explanation:** Digoxin toxicity is a high-yield topic in NEET-PG, characterized by increased automaticity and decreased conduction velocity. **1. Why Option A is the Correct Answer (The Exception):** The question asks for the statement that is **NOT** true. While **Bidirectional Ventricular Tachycardia** (where the QRS axis alternates beat-to-beat) is a classic and highly specific sign of Digoxin toxicity, **Biventricular Tachycardia** is a misnomer/incorrect term in this clinical context. The hallmark arrhythmia is *Bidirectional*, not *Biventricular*. **2. Analysis of Other Options:** * **Option B (PAT with Block):** This is the **most characteristic** arrhythmia of Digoxin toxicity. Digoxin increases atrial automaticity (causing tachycardia) while simultaneously increasing vagal tone to the AV node (causing block). * **Option C (Ventricular Bigeminy):** This is the **most common** arrhythmia seen in Digoxin toxicity. It occurs due to delayed after-depolarizations (DADs) caused by intracellular calcium overload. * **Option D (Treatment of Atrial Fibrillation):** This is a true statement regarding the *therapeutic use* of Digoxin. It is used in AFib to control the ventricular rate due to its vagomimetic action on the AV node, though it is no longer first-line. **Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits Na+/K+ ATPase pump → increased intracellular Na+ → decreased Na+/Ca2+ exchange → increased intracellular Ca2+ (positive inotropy). * **ECG Changes:** Earliest sign is prolonged PR interval. The "Reverse Tick" or "Sagging" ST-segment depression is a sign of Digoxin *effect*, not necessarily toxicity. * **Electrolyte Triggers:** Hypokalemia, Hypomagnesemia, and Hypercalcemia predispose to toxicity. * **Antidote:** Digoxin-specific Fab fragments (Digibind).

Q: Drugs associated with clinically useful or physiologically important positive inotropic effects include all of the following except?

Enalapril. **Explanation:** The core of this question lies in understanding the mechanism of **Inotropy** (the force of myocardial contraction). Positive inotropic agents increase the concentration of intracellular calcium or the sensitivity of contractile proteins to calcium, thereby increasing cardiac output. **Why Enalapril is the Correct Answer:** **Enalapril** is an **ACE Inhibitor**. Its primary mechanism involves inhibiting the conversion of Angiotensin I to Angiotensin II and preventing the breakdown of bradykinin. This leads to systemic vasodilation (decreased afterload) and reduced salt/water retention (decreased preload). While Enalapril is a cornerstone in treating Heart Failure because it reduces cardiac workload and prevents remodeling, it has **no direct positive inotropic effect** on the myocardium. **Analysis of Incorrect Options:** * **Amrinone (and Milrinone):** These are **PDE-3 inhibitors**. They prevent the breakdown of cAMP in cardiac muscle, leading to increased calcium influx and increased contractility (Inodilators). * **Digoxin:** A **Cardiac Glycoside** that inhibits the Na+/K+ ATPase pump. This indirectly leads to an increase in intracellular calcium via the Na+/Ca2+ exchanger, resulting in a potent positive inotropic effect. * **Dobutamine:** A selective **Beta-1 agonist**. It stimulates Gs-coupled receptors to increase cAMP, directly enhancing myocardial contractility. **NEET-PG High-Yield Pearls:** * **Inodilators:** Drugs like Milrinone and Levosimendan provide both positive inotropy and vasodilation. * **Levosimendan:** Acts as a **Calcium sensitizer**; it increases contractility without increasing myocardial oxygen demand significantly. * **ACE Inhibitors:** Known as "Life-prolonging drugs" in heart failure, but they are **not** inotropes. * **Digoxin Toxicity:** Characterized by xanthopsia (yellow vision) and various arrhythmias (most specific being Atrial Tachycardia with AV block).

Q: Which of the following anti-angina drugs acts by inhibition of long-chain 3-ketoacyl coenzyme A thiolase?

Trimetazidine. ### Explanation **Correct Option: A. Trimetazidine** Trimetazidine is a **pFOX inhibitor** (partial fatty acid oxidation inhibitor). It works by inhibiting the enzyme **long-chain 3-ketoacyl coenzyme A thiolase (3-KAT)**. * **Mechanism:** Under normal conditions, the heart derives energy from fatty acid oxidation, which requires more oxygen. By inhibiting 3-KAT, Trimetazidine shifts myocardial metabolism from fatty acid oxidation to **glucose oxidation**. * **Benefit:** Glucose oxidation is more oxygen-efficient, allowing the heart to produce more ATP per molecule of oxygen consumed, thereby protecting the myocardium during ischemic episodes without affecting heart rate or blood pressure. **Incorrect Options:** * **B. Ivabradine:** Acts by selectively inhibiting the **funny current ($I_f$)** in the sinoatrial (SA) node. It reduces heart rate without affecting myocardial contractility or BP. * **C. Ranolazine:** Primarily acts by inhibiting the **late inward sodium current ($I_{Na}$)** in cardiomyocytes. This prevents calcium overload and improves diastolic relaxation. * **D. Nicorandil:** A dual-action drug that acts as a **K+ATP channel opener** (causing arterial vasodilation) and a **Nitric Oxide (NO) donor** (causing venodilation). **High-Yield Clinical Pearls for NEET-PG:** * **Trimetazidine** is often used as add-on therapy in stable angina; however, it is contraindicated in patients with **Parkinson’s disease** as it may worsen extrapyramidal symptoms. * **Ivabradine** is specifically indicated in patients with stable angina who have a contraindication to Beta-blockers, provided they are in **sinus rhythm**. * **Nicorandil** can cause a unique side effect: **persistent mucosal ulcerations** (e.g., oral, anal, or GI ulcers).

Q: Which of the following antihypertensive drugs inhibits the vesicular uptake of norepinephrine?

Reserpine. ### Explanation **Correct Option: C. Reserpine** Reserpine is an alkaloid derived from *Rauwolfia serpentina*. Its primary mechanism of action is the **irreversible inhibition of the Vesicular Monoamine Transporter (VMAT-2)**. * **Mechanism:** Under normal conditions, VMAT-2 transports free norepinephrine (NE), dopamine, and serotonin from the cytoplasm into storage vesicles. By blocking VMAT-2, reserpine prevents the vesicular uptake and storage of these neurotransmitters. * **Result:** The unprotected NE in the cytoplasm is degraded by the enzyme **Monoamine Oxidase (MAO)**, leading to a profound depletion of catecholamines in sympathetic nerve terminals, which results in a decrease in blood pressure and heart rate. **Analysis of Incorrect Options:** * **A. Propranolol:** A non-selective **beta-blocker** ($β_1$ and $β_2$). it acts by antagonizing adrenergic receptors, not by affecting neurotransmitter storage or uptake. * **B. Prazosin:** A selective **alpha-1 ($α_1$) blocker**. It causes vasodilation by blocking postsynaptic receptors on vascular smooth muscle. * **D. Guanethidine:** This drug inhibits the **release** of norepinephrine from the nerve terminal and displaces NE from vesicles, but it does not primarily act by inhibiting the VMAT-2 uptake pump like reserpine. **High-Yield Clinical Pearls for NEET-PG:** * **Depression Warning:** Because reserpine also depletes serotonin and dopamine in the CNS, it is notorious for causing **severe mental depression** and is contraindicated in patients with a history of depressive illness. * **Gastrointestinal Effects:** By depleting sympathetic tone, it leads to parasympathetic dominance, causing increased gastric acid secretion (risking peptic ulcers) and diarrhea. * **VMAT-1 vs VMAT-2:** VMAT-1 is found in neuroendocrine cells (adrenal medulla), while **VMAT-2** is the primary target in the CNS and peripheral postganglionic neurons.

Q: Which ECG findings represent a characteristic manifestation of digitalis toxicity?

Atrial tachycardia with variable block. **Explanation:** **Atrial tachycardia with variable AV block** is considered the most characteristic (pathognomonic) arrhythmia of digitalis toxicity. This occurs due to the dual action of Digoxin: 1. **Increased Automaticity:** Digoxin inhibits the Na+/K+ ATPase pump, leading to intracellular Calcium overload, which increases the firing rate of atrial ectopic foci (causing tachycardia). 2. **Increased Vagomimetic Effect:** Digoxin increases vagal tone, which slows conduction through the AV node (causing the block). The combination of a rapid atrial rate with a blocked conduction is a classic "signature" of Digoxin overdose. **Analysis of Incorrect Options:** * **A & B (ST-segment depression and T-wave inversion):** These are common ECG changes seen with **therapeutic** doses of Digoxin (often described as a "reverse tick" or "scooped" ST segment). While present in toxicity, they are not specific to it. * **C (Atrial flutter):** Digoxin is actually used to treat atrial flutter by increasing the AV block; it is rarely caused by the drug itself. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Arrhythmia:** Ventricular Bigeminy (PVCs). * **Most Characteristic Arrhythmia:** Atrial tachycardia with block. * **Most Common Cause of Death:** Ventricular Fibrillation. * **Electrolyte Triggers:** Hypokalemia, Hypomagnesemia, and Hypercalcemia predispose to toxicity. * **Antidote:** Digoxin-specific antibody fragments (DigiFab/Digibind). * **Visual Side Effect:** Xanthopsia (yellowish-green vision).

Q: What is the drug available for the treatment of resistant cases of atrial fibrillation?

Amiodarone. **Explanation:** **Amiodarone** is the drug of choice for resistant or refractory atrial fibrillation (AF) due to its unique pharmacological profile. It is a Class III antiarrhythmic that primarily blocks potassium channels, prolonging the action potential duration and effective refractory period. However, it also possesses Class I (sodium channel), Class II (beta-blocking), and Class IV (calcium channel) activities. This "broad-spectrum" effect makes it highly effective in maintaining sinus rhythm when other agents fail, especially in patients with structural heart disease or heart failure. **Why other options are incorrect:** * **Quinidine (Class IA):** While it can convert AF to sinus rhythm, it is rarely used today due to significant side effects (cinchonism, thrombocytopenia) and the risk of "Quinidine syncope" caused by Torsades de Pointes. * **Propranolol (Class II):** Beta-blockers are excellent for **rate control** in AF, but they are generally not effective for converting resistant AF back to sinus rhythm (rhythm control). * **Digoxin:** It is used for rate control in AF, particularly in sedentary patients or those with heart failure. However, it is ineffective for rhythm conversion and does not work well during high-sympathetic states (like exercise). **Clinical Pearls for NEET-PG:** * **Drug of Choice:** Amiodarone is the preferred drug for AF in patients with **congestive heart failure (CHF)** or myocardial infarction. * **Side Effects:** High-yield for exams! Watch for pulmonary fibrosis, thyroid dysfunction (due to high iodine content), corneal microdeposits, and "blue-gray" skin discoloration. * **Monitoring:** Patients on long-term Amiodarone require periodic Liver Function Tests (LFTs), Thyroid Function Tests (TFTs), and Chest X-rays.

Question 1

A 40-year-old male presents to the emergency department with an altered level of consciousness. On examination, his blood pressure is 210/152 mmHg and he has severe papilledema. Which of the following drugs, administered via intravenous infusion, acts on GPCRs and has a very short duration of action?

Accepted Answer

Fenoldopam

Answer

Hydralazine

Answer

Metoprolol

Answer

Nitroprusside

Question 2

All are true about Carvedilol except?

Accepted Answer

It is a cardioselective beta-blocker

Answer

Used in chronic congestive heart failure

Answer

It also has antioxidant and anti-inflammatory properties

Answer

Beta-blockers are started at low doses and gradually increased till maximum recommended dose

Question 3

The toxic effect of beta receptor antagonists includes all of the following EXCEPT?

Accepted Answer

Precipitate migrainic effect

Answer

Hypoglycemic episodes in diabetes

Answer

Worsening of preexisting asthma

Answer

Ischemic cardiac episode on abrupt discontinuation

Question 4

Organic nitrates can lead to the development of tolerance when used chronically. Which of the following preparations is least likely to develop tolerance?

Accepted Answer

Sublingual nitroglycerine

Answer

Sustained release oral nitroglycerine

Answer

Transdermal nitroglycerine

Answer

Oral pentaerythritol tetranitrate

Question 5

All of the following statements about Digoxin-induced arrhythmias are true, EXCEPT?

Accepted Answer

Biventricular Tachycardia

Answer

Paroxysmal Atrial Tachycardia with variable AV Block

Answer

Ventricular Bigeminy

Answer

May be used to treat Atrial Fibrillation

Question 6

Drugs associated with clinically useful or physiologically important positive inotropic effects include all of the following except?

Accepted Answer

Enalapril

Answer

Amrinone

Answer

Digoxin

Answer

Dobutamine

Question 7

Which of the following anti-angina drugs acts by inhibition of long-chain 3-ketoacyl coenzyme A thiolase?

Accepted Answer

Trimetazidine

Answer

Ivabradine

Answer

Ranolazine

Answer

Nicorandil

Question 8

Which of the following antihypertensive drugs inhibits the vesicular uptake of norepinephrine?

Accepted Answer

Reserpine

Answer

Propranolol

Answer

Prazosin

Answer

Guanithidine

Question 9

Which ECG findings represent a characteristic manifestation of digitalis toxicity?

Accepted Answer

Atrial tachycardia with variable block

Answer

ST-segment depression

Answer

T-wave inversion

Answer

Atrial flutter

Question 10

What is the drug available for the treatment of resistant cases of atrial fibrillation?

Accepted Answer

Amiodarone

Answer

Quinidine

Answer

Propranolol

Answer

Digoxin

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?